Edding Genor Group Holdings

Edding Genor Group Holdings is a leading integrated biopharmaceutical company formed through the strategic merger of Genor Biopharma and Eddingpharm. The company possesses a comprehensive value chain encompassing advanced biologics R&D, large-scale GMP manufacturing, and a robust commercialization network across China. Its portfolio focuses on high-growth therapeutic areas including oncology, immunology, and anti-infectives, featuring both internally developed innovative biologics and in-licensed specialty drugs. With multiple products already on the market, such as Vancocin and Ceclor, and a deep clinical pipeline including CDK4/6 inhibitors and bispecific antibodies, the group is well-positioned to address significant unmet medical needs. Edding Genor leverages its dual expertise in drug discovery and market access to drive growth in the Greater China region and beyond.